Supplemental Table 1. Baseline characteristics

	Group A (n = 30)	Group B (n = 30)	p-value
Age (years)	72 ± 12	78 ± 5	0.31
Female	66%	83.3%	0.72
Body mass index	1.8 ± 0.2	1.8 ± 0.3	1
NYHA I-II	80%	83.3%	1
NYHA III-IV	20%	16.7%	1
CCS I-II	96.6%	100%	1
CCS III-IV	3.3%	0	-
Previous MI	6.6%	3.3%	1
Atrial Fibrillation	6.6%	13.3%	0.41
LV good (EF> 50%)	93.3%	63.3%	0.47
LV moderate (EF < 50%, > 30%)	2	11	0.04
LV poor (EF < 30%)	-	-	-
Chronic pulmonary disease	3.3%	-	-
CVA/TIA	-	3.3%	-

IDDM	3.3%	6.6%	1
NIDDM	16.6%	20%	1
Extracardiac arteriopathy	3.3%	16.6%	0.21
Creatinine (g/dl)	0.8 ± 0.3	0.9 ± 0.4	1
HCT (%)	33.3 ± 4.9	35.7 ± 6.2	0.15
Hb (g/dl)	10 ± 1.3	10.6 ± 1.5	0.16
ES II	1.2 ± 0.3	1.4 ± 0.4	0.43

Group A: dopamine (2 mg bolus); Group B: control. Values are presented as the median (interquartile range), mean ± standard deviation, or n (%). CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; CVA, cerebral vascular accident; EF, ejection fraction; ES, Euroscore; HCT, hematocrit; Hb, hemoglobin; IDDM, insulin-dependent diabetes mellitus; LV, left ventricular function; MI, myocardial infarction; NIDDM, non-insulin-dependent diabetes mellitus; NYHA, New York Heart Association; TIA, transient ischemic attack.